tbuckley/cabot-search huggingface dataset:
511TiP A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC
Authors: D. Zhang, C. Bai, J. Zhang, Y. Zhang, T. Liu, H. Pan, H. Zhong, X. Lin, W-S. Qiu, Y. Liu, X. Yuan, T. Zhang, X. Yin, Y. Deng, X. Hu, R. Xu
Journal: Annals of Oncology (2021)
Abstract 11343: Accelerated Aortic Stiffening Relative to Carotid Stiffness is Associated With Cognitive Decline: The Whitehall II Study
Authors: Scott T Chiesa, Stefano Masi, Martin J Shipley, Elizabeth Ellins, Julian P Halcox, Alan Fraser, Alun D Hughes, Riyaz S Patel, Ashraf W Khir, Eric J Brunner, Archana Singh-Manoux, Mika Kivimaki, David Celermajer, John E Deanfield
Journal: Circulation (2019)

Introduction: Excessive stiffening of the highly elastic aorta relative to the carotid artery may reduce impedance mismatch at their bifurcation and increase transmission of potentially-damaging pu...
A world on the edge of climate disaster
Authors: Fiona Godlee
Journal: BMJ (2021)

The world is heating up and so is the urgency for action. Without radical change in the way we live, move, eat, work, and play, rising global temperatures will result in irreversible planetary change, with catastrophic consequences for humanity. These are strong words but they are backed by science. The International Panel on Climate Change says that, to keep the post-industrial global temperature rise below the tipping point of 1.5°C, the world must halve its emissions of carbon dioxide and other greenhouse gases by 2030 and reach net zero by 2050. At current rates of …
Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction–Associated Fatty Liver Disease Patients Referred From Primary Care
Authors: Zhengyi Wang, Luis Calzadilla Bertot, Gary P Jeffrey, John Joseph, George Garas, Bastiaan de Boer, Yi Huang, Gerry MacQuillan, Michael Wallace, Briohny Smith, Leon A Adams
Journal: Clinical Gastroenterology and Hepatology (2021)
1205P Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US
Authors: M.O. Jahanzeb, H.M. Lin, Y. Wu, M. Gorritz, C.B. McGuiness, K. Sun, C-C. Chen, P. Zhang, D.R. Camidge
Journal: Annals of Oncology (2021)
157P Moderate physical activity (MPA) modulates immune system in breast cancer (BC) patients during preoperative chemotherapy: The NEO-RUNNER study
Authors: O. Garrone, M. Paccagnella, F. Ruatta, A. Abbona, A. Falletta, N. Croce, P. Vanella, N. Denaro, D. Rubini, C. Gallo, L. Rivoltini, M.C. Merlano
Journal: Annals of Oncology (2021)
CN41 Advanced practice nurse management in multiple myeloma treated with lenalidomide dexamethasone: “A new challenge”?
Authors: M. Sapet, C. Migala, E. Daguenet, P. Collet, K. Boussoualim, T. Thomas, D. Guyotat, K. Augeul-Meunier
Journal: Annals of Oncology (2021)
1258P MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study
Authors: H. Babey, P. Jamme, R. Gervais, J-B. Assié, R. Veillon, H. Doubre, M. Pérol, F. Guisier, E. Huchot, C. Decroisette, L. Falchero, A-M. Chiappa, M. André, A.B. Cortot, C. Chouaid, G. Le Gac, R. Descourt
Journal: Annals of Oncology (2021)
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Authors: Kelly M. Chin, Olivier Sitbon, Martin Doelberg, Jeremy Feldman, J. Simon R. Gibbs, Ekkehard Grünig, Marius M. Hoeper, Nicolas Martin, Stephen C. Mathai, Vallerie V. McLaughlin, Loïc Perchenet, David Poch, Rajan Saggar, Gérald Simonneau, Nazzareno Galiè
Journal: Journal of the American College of Cardiology (2021)

In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with initial double oral therapy.TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension; NCT02558231), a multicenter, double-blind, randomized phase 3b study, evaluated initial triple (macitentan, tadalafil, and selexipag) versus initial double (macitentan, tadalafil, and placebo) oral therapy in newly diagnosed, treatment-naive patients with PAH.Efficacy was assessed until the last patient randomized completed week 26 (end of main observation period). The primary endpoint was change in pulmonary vascular resistance (PVR) at week 26.Patients were assigned to initial triple (n = 123) or initial double therapy (n = 124). At week 26, both treatment strategies reduced PVR compared with baseline (by 54% and 52%), with no significant difference between groups (ratio of geometric means: 0.96; 95% confidence interval: 0.86-1.07; P = 0.42). Six-minute walk distance and N-terminal pro-brain natriuretic peptide improved by week 26, with no difference between groups. Risk for disease progression (to end of main observation period) was reduced with initial triple versus initial double therapy (hazard ratio: 0.59; 95% confidence interval: 0.32-1.09). Most common adverse events with initial triple therapy included headache, diarrhea, and nausea. By the end of the main observation period, 2 patients in the initial triple and 9 in the initial double therapy groups had died.In patients with newly diagnosed PAH, both treatment strategies markedly reduced PVR by week 26, with no significant difference between groups (primary endpoint not met). Exploratory analyses suggested a possible signal for improved long-term outcomes with initial triple versus initial double oral therapy.
1641P Patient preferences towards the application of telemedicine on cancer care during Coronavirus disease 2019 (COVID-19) pandemic. ONCOTELEMED STUDY
Authors: P. Ribera, C. Climent, S. Soriano, I. Macias Declara, L. Fernandez, L. Vilà, M.A. Segui, C. Pericay
Journal: Annals of Oncology (2021)
866P ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC)
Authors: M. Forster, R. Mendes, T. Guerrero Urbano, M. Evans, M. Lei, V. Spanswick, E. Miles, R. Simões, G. Wheeler, S. Forsyth, L. White
Journal: Annals of Oncology (2021)
Abstract 27: Is Butter Back? A Systematic Review and Meta-analysis of Butter Consumption and Risk of Cardiovascular Disease, Diabetes, and Total Mortality
Authors: Laura Pimpin, Jason Wu, Hila Haskelberg, Liana Del Gobbo, Dariush Mozaffarian
Journal: Circulation (2016)

Introduction: Dietary guidelines recommend avoiding foods high in saturated fat. Yet, emerging evidence suggests potential cardiometabolic benefits of dairy products and dairy fat. Evidence on the role of butter, with high saturated dairy fat content, for total mortality, CVD, and diabetes remains unclear. Objective: To systematically investigate the prospective association of butter consumption with all-cause mortality, CVD, and type 2 diabetes. Methods: We searched 9 databases from inception to May 2015 without restriction on publication year, setting, or language, using keywords related to butter intake and outcomes of interest. We included prospective cohorts or randomized clinical trials providing estimates of effects of butter intake on mortality, CVD (including CHD or stroke), or diabetes in general adult populations. Inclusion decisions and data extractions were performed independently and in duplicate, including on study and participant characteristics, exposure and outcome definitions and assessments, analysis methods, and adjusted risk estimates and uncertainty of prospective multivariate associations. Study quality was evaluated by a modified Newcastle-Ottawa score. Findings were pooled by random and fixed effects meta-analysis, with heterogeneity assessed by the I2 statistic and publication bias by Egger’s test and funnel plots. Results: We identified 9 publications including 15 country-specific cohorts, with 636,151 unique participants, 6.5 million person-years of follow-up, and 28,271 total deaths, 9,783 cases of incident CVD, and 23,954 cases of incident diabetes. Quality ratings were high for all studies. Butter consumption was weakly associated with all-cause mortality (N=9 country-specific cohorts; per 14 g (1 tablespoon)/day: RR=1.01, 95%CI=1.00, 1.03, P=0.045); was not significantly associated with any CVD (N=4; RR=1.00, 95%CI=0.98, 1.02; P=0.79), CHD (N=3; RR=0.99, 95%CI=0.96, 1.03; P=0.605), or stroke (N=3; RR=1.00, 95%CI=0.98, 1.03; P=0.79), and was inversely associated with incidence of diabetes (N=11; RR=0.96, 95%CI=0.93, 0.99; P=0.02). We did not identify evidence for heterogeneity nor publication bias. Conclusions: This systematic review and meta-analysis identified a weak association of butter intake with total mortality, no association with CVD, and a modest protective association with diabetes. The studies identified indicate that many global cohorts have not reported on these associations; if publication bias exists, it would likely be for unpublished reports with null findings, rather than significant associations. In sum, these results suggest relatively neutral effects of butter consumption on major health outcomes, with a possible modest benefit for diabetes.
133P Magnetic resonance imaging radiomics predicts high and low recurrence risk and is associated with LncRNAs in early-stage invasive breast cancer
Authors: W. Ren, Y. Yu, Z. He, L. Mao, Y. Chen, W. Ouyang, Y. Tan, C. Li, K. Chen, J. Ouyang, Q. Hu, C. Xie, H. Yao
Journal: Annals of Oncology (2021)
909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
Authors: X. Chen, C. Hu, W. Wang, Q. Zou, J. Li, Q. Lin, X. Zhu, Y. Jiang, Y. Sun, L. Shen, L. Wang, G. Zou, X. Lin, Y. Wang, S. Lin, M. Li, R. Ao, R. Xu, H. Lin, R. Wang
Journal: Annals of Oncology (2021)
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Authors: Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, Timothy J. Voorhees, Anson Snow, Natalie Sophia Grover, Amy Ayers, Jason Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A. Ollila, Christopher Del Prete, Adam Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Ahsan Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey Switchenko, Jonathon Cohen, Craig A. Portell
Journal: Blood (2021)
182P Correlation between TILs, ALDH1 and PD-L1 expression in triple-negative (TN) and HER2-positive (HER2+) breast cancer (BC)
Authors: M. López Flores, E. Honrado Franco, L.F. Sánchez Couisido, C. Minguito Carazo, M.E. Vallejo Pascual, O. Sanz Guadarrama, A. García Palomo, A.J. Molina de la Torre, A. López González
Journal: Annals of Oncology (2021)
Where they sing solo: Accounting for cross-cultural variation in collective music-making in theories of music evolution
Authors: Aniruddh D. Patel, Chris von Rueden
Journal: Behavioral and Brain Sciences (2021)

Abstract Collective, synchronous music-making is far from ubiquitous across traditional, small-scale societies. We describe societies that lack collective music and offer hypotheses to help explain this cultural variation. Without identifying the factors that explain variation in collective music-making across these societies, theories of music evolution based on social bonding (Savage et al.) or coalition signaling (Mehr et al.) remain incomplete.
Extramedullary Manifestations in World Health Organization-Defined Chronic Myelomonocytic Leukemia: Clinical, Molecular and Prognostic Correlates
Authors: Katherine Hoversten, Rangit Vallapureddy, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik
Journal: Blood (2017)
716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
Authors: T.B. Powles, J.E. Gschwend, S. Bracarda, D. Castellano, M. Gross-Goupil, J. Bjerggaard Jensen, A. Kann, H. Nishiyama, L. Makaroff, H. Lassidi, S. Mariathasan, J. Zhang, V. Degaonkar, J. Bellmunt
Journal: Annals of Oncology (2021)
Changes in Supplemental Nutrition Assistance Program Policies and Diabetes Prevalence: Analysis of Behavioral Risk Factor Surveillance System Data From 2004 to 2014
Authors: Sameed Ahmed M. Khatana, Nicholas Illenberger, Rachel M. Werner, Peter W. Groeneveld, Nandita Mitra
Journal: Diabetes Care (2021)

OBJECTIVE Food insecurity is associated with diabetes. The Supplemental Nutrition Assistance Program (SNAP) is the largest U.S. government food assistance program. Whether such programs impact diabetes trends is unclear. The objective of this study was to evaluate the association between changes in state-level policies affecting SNAP participation and county-level diabetes prevalence. RESEARCH DESIGN AND METHODS We evaluated the association between change in county-level diabetes prevalence and changes in the U.S. Department of Agriculture SNAP policy index—a measure of adoption of state-level policies associated with increased SNAP participation (higher value indicating adoption of more policies associated with increased SNAP participation; range 1–10)—from 2004 to 2014 using g-computation, a robust causal inference methodology. The study included all U.S. counties with diabetes prevalence data available from the Centers for Disease Control and Prevention’s U.S. Diabetes Surveillance System. RESULTS The study included 3,135 of 3,143 U.S. counties. Mean diabetes prevalence increased from 7.3% (SD 1.3) in 2004 to 9.1% (SD 1.8) in 2014. The mean SNAP policy index increased from 6.4 (SD 0.9) to 8.2 (SD 0.6) in 2014. After accounting for changes in demographic-, economic-, and health care-related variables and the baseline SNAP policy index, a 1-point absolute increase in the SNAP policy index between 2004 and 2014 was associated with a 0.050 (95% CI 0.042–0.057) percentage point lower diabetes prevalence per year. CONCLUSIONS State policies aimed at increasing SNAP participation were independently associated with a lower rise in diabetes prevalence between 2004 and 2014.
COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect
Authors: Vinay Guduguntla, Mitchell H. Katz
Journal: JAMA Internal Medicine (2021)

Anthony Simone, MD; John Herald, MD; Aiyu Chen, MPH; Neil Gulati, MD; Albert Yuh-Jer Shen, MD; Bruno Lewin, MD; Ming-Sum Lee, MD, PhD
Weather, air pollution, and SARS-CoV-2 transmission: a global analysis
Authors: Ran Xu, Hazhir Rahmandad, Marichi Gupta, Catherine DiGennaro, Navid Ghaffarzadegan, Heresh Amini, Mohammad S Jalali
Journal: The Lancet Planetary Health (2021)

BackgroundUnderstanding how environmental factors affect SARS-CoV-2 transmission could inform global containment efforts. Despite high scientific and public interest and multiple research reports, there is currently no consensus on the association of environmental factors and SARS-CoV-2 transmission. To address this research gap, we aimed to assess the relative risk of transmission associated with weather conditions and ambient air pollution.MethodsIn this global analysis, we adjusted for the delay between infection and detection, estimated the daily reproduction number at 3739 global locations during the COVID-19 pandemic up until late April, 2020, and investigated its associations with daily local weather conditions (ie, temperature, humidity, precipitation, snowfall, moon illumination, sunlight hours, ultraviolet index, cloud cover, wind speed and direction, and pressure data) and ambient air pollution (ie, PM2·5, nitrogen dioxide, ozone, and sulphur dioxide). To account for other confounding factors, we included both location-specific fixed effects and trends, controlling for between-location differences and heterogeneities in locations' responses over time. We built confidence in our estimations through synthetic data, robustness, and sensitivity analyses, and provided year-round global projections for weather-related risk of global SARS-CoV-2 transmission.FindingsOur dataset included data collected between Dec 12, 2019, and April 22, 2020. Several weather variables and ambient air pollution were associated with the spread of SARS-CoV-2 across 3739 global locations. We found a moderate, negative relationship between the estimated reproduction number and temperatures warmer than 25°C (a decrease of 3·7% [95% CI 1·9–5·4] per additional degree), a U-shaped relationship with outdoor ultraviolet exposure, and weaker positive associations with air pressure, wind speed, precipitation, diurnal temperature, sulphur dioxide, and ozone. Results were robust to multiple assumptions. Independent research building on our estimates provides strong support for the resulting projections across nations.InterpretationWarmer temperature and moderate outdoor ultraviolet exposure result in a slight reduction in the transmission of SARS-CoV-2; however, changes in weather or air pollution alone are not enough to contain the spread of SARS-CoV-2 with other factors having greater effects.FundingNone.
1086P IBI310 alone or in combination with sintilimab for advanced melanoma: Updated results of a phase Ia/Ib study
Authors: B. Lian, C. Cui, L. Si, Z. Chi, X. Sheng, L. Mao, X. Wang, B. Tang, X. Bai, X. Yan, S. Li, L. Zhou, H. Zhou, Y. Wang, Q-S. Hou, J. Guo
Journal: Annals of Oncology (2021)
425P Cetuximab could be administered once every two weeks instead of once weekly
Authors: S. Lobet, G. Paintaud, N. Azzopardi, C. Passot, M. Caulet, R. Chautard, C. Vignault-Desvignes, O. Capitain, D. Tougeron, M. Boisdron-Celle, D. Ternant, T. Lecomte
Journal: Annals of Oncology (2021)
Smoking Cessation Improves Outcomes in Patients With Peripheral Artery Disease
Authors: Mark A. Creager, Naomi M. Hamburg
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
80P Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN
Authors: M. Saori, Y. Nakamura, K. Sawada, S. Horasawa, S. Kadowaki, K. Kato, M. Ueno, E. Oki, T. Satoh, Y. Komatsu, H. Tukachinsky, J. Lee, R. Madison, E. Sokol, D. Pavlick, A. Aiyer, D. Fabrizio, J. Venstrom, G. Oxnard, T. Yoshino
Journal: Annals of Oncology (2021)
TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion
Authors: Joanne Hsieh, Matthew M. Molusky, Kristin M. McCabe, Panagiotis Fotakis, Tong Xiao, Liana Tascau, Lars Zeana-Schliep, Paul DaSilva-Jardine, Alan R. Tall
Journal: Journal of Hepatology (2021)
Characteristics of the Gut Microbiota and Metabolism in Patients With Latent Autoimmune Diabetes in Adults: A Case-Control Study
Authors: Yuanyuan Fang, Chenhong Zhang, Hongcai Shi, Wei Wei, Jing Shang, Ruizhi Zheng, Lu Yu, Pingping Wang, Junpeng Yang, Xinru Deng, Yun Zhang, Shasha Tang, Xiaoyang Shi, Yalei Liu, Huihui Yang, Qian Yuan, Rui Zhai, Huijuan Yuan
Journal: Diabetes Care (2021)

OBJECTIVE Type 1 and type 2 diabetes are associated with gut dysbiosis. However, the relationship between the gut microbiota and latent autoimmune diabetes in adults (LADA), sharing clinical and metabolic features with classic type 1 and type 2 diabetes, remains unclear. Here, we used a multiomics approach to identify the characteristics of the gut microbiota and metabolic profiles in patients with LADA. RESEARCH DESIGN AND METHODS This age- and sex-matched case-control study included 30 patients with LADA, 29 patients with classic type 1 diabetes, 31 patients with type 2 diabetes, and 29 healthy individuals. The gut microbiota profiles were identified through the 16S rRNA gene, and fecal and serum metabolites were measured through untargeted liquid chromatography-mass spectrometry. RESULTS Patients with LADA had a significantly different structure and composition of the gut microbiota and their metabolites as well as a severe deficiency of short-chain fatty acid–producing bacteria. The gut microbiota structure of the patients with LADA was more similar to that of patients with type 1 diabetes who were positive for GAD antibody. We identified seven serum metabolite modules and eight fecal metabolite modules that differed between the LADA group and the other groups. CONCLUSIONS The characteristic gut microbiota and related metabolites of patients with LADA are associated with autoantibodies, glucose metabolism, islet function, and inflammatory factors, which may contribute to the pathogenesis of LADA. Future longitudinal studies should explore whether modulating the gut microbiota and related metabolites can alter the natural course of autoimmune diabetes in the quest for new therapeutics.
394P Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial
Authors: T. Aparicio, O. Bouche, P.L. Etienne, E. Barbier, L. Mineur, R. Desgrippes, F. Hocine, J.J. Martin, V. Lebrun-Ly, J. Crétin, J. Desrame, Y. Rinaldi, L. Cany, C. Falandry, E. Terrebonne, L. Mosser, M. Pauwels, A. Turpin, M. Van den Eynde, S. Hiret
Journal: Annals of Oncology (2021)
24P The STAT3 phosphorylation status discriminates tumor associated populations in myeloid cell tumor-infiltrating model
Authors: E.B. Palmeiro, M. Ibañez, C. Hernández, L. Chocarro, H. Arasanz, A. Bocanegra, J. Fernandez, E. Santamaria, R. Vera, C. Smerdou, D. Escors, G. Kochan
Journal: Annals of Oncology (2021)